Cell and Advanced Therapies Supply Chain Management Market, 2020-2030

(Công ty cong tu dong hcm - https://baophuc.vn)

• Báo giá Trọn gói Thi công Cửa Tự Động
• Cách lấy mã xác nhận để có thể đăng ký, đăng bài, bình luận trên diễn đàn này
• Kho giao diện đẹp dành cho Blogspot
• Bộ tài liệu Khóa Học hỗ trợ Marketing Online, SEO, MMO miễn phí hàng đầu tại Việt Nam

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption.

Key Inclusions

· A detailed assessment of the current market landscape, featuring a comprehensive list of over 160 technological platforms that are being used to manage the cell and advanced supply chain therapies, along with information on the different types of software systems (COP, EMS, IMS, LIMS , LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service , traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs , hospitals, research institutes, commercial organizations, and others),applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgrade, validation and testing, and others).

· An insightful company Competitiveness analysis, taking Into Consideration the supplier power (based on chúng employee base and years of experience in the industry) and portfolio-related parameters, như number of software solutions Offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits.

· Comprehensive profiles of industry players offering software solutions được hiện for Supply Chain Management, featuring an overview of the company, its Financial Information (if available), and a detailed description of its software system (s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.

· A detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, như donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.

· A qualitative assessment of the current and of long-term needs of Different stakeholders (Patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / Payers cell) Involved in the cell and advanced therapies supply chain, featuring a summary of the DIVERSE needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address such issues.

· An analysis of the various stages of Investments made at development, như seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies in this field được ENGAGED.

· An analysis of the partnerships có được established in the domain, in the period Between 2014 and Q3 2019, covering Software Licensing Agreements, mergers and Acquisitions, Product Development Agreements, product integration Agreements, distribution Agreements, asset purchase Agreements, and other the relevant deals.

· A detailed analysis of the use cases where the aforementioned Utilization platform software systems were leveraged by various stakeholders in the domain, in the period 2014 and Q3 2019 giữa, highlighting the ways companies have thực vd chứa systems To improve / optimize various supply chain- related processes of cell and advanced therapies.

· An in-depth analysis of the cost saving potencial across various processes of the cell and advanced therapies có thể supply chain Brought about by the an implementation of bespoke and integrated Technological solutions / software systems.

· A case study on Cops, featuring insights on key functions and an implementation strategies có, khi có am also considering other Strategic position and connectivity with adjacent systems and advanced cell therapies trong supply chain. In addition, it provides a brief discussion on the growing popularity of COPs on the social media platform, Twitter.

The USD 1.5 billion (by 2030) financial opportunity within the cell and advanced therapies supply chain management market has been analyzed across the following segments:

Application area

· Sample collection and processing

· Manufacturing

· Logistics

· Patient identification and treatment follow-up

Type of software solution

· Cell orchestration platform

· Enterprise manufacturing system

· Inventory management system

· Laboratory information management system

· Logistics management system

· Patient management system

· Quality management system

Mode of Deployment

· Cloud-based solution

· On-premises solution

Scale of Operation

· Clinical

· Commercial

End user

· Biobank

· Cell therapy lab / commercial organization

· Hospital / medical center

· Research institute

Key geographical regions

· North America

· Europe

· Asia Pacific

· Rest of the world